Michael A.  Gaul net worth and biography

Michael Gaul Biography and Net Worth

COO of Beyond Air

Michael Gaul joined Beyond Air as its Senior VP, Operations in May 2020. Mr. Gaul has a proven track record in multiple industries, including medical devices and reagents, semiconductor automation capital equipment, public safety communication systems, and complex industrial controls and instrumentation. He has led teams in operations, sales and marketing, supply chain, distribution, quality, regulatory, human resources, and finance.

He has P&L experience with multiplant responsibility in both the US and Asia, including roles with Sparton Corporation (Group VP, Manufacturing & Design Services Business Unit; Group VP, Medical Business Unit), SynCardia Systems (COO; VP Operations), Ventana Medical Systems (VP & General Manager, Operations), and Robotic Vision Systems, Inc (General Manager, Vanguard Division; VP Operations, Systemation Division).

He currently serves on the Board of Directors of BioOhio to support and promote Ohio’s bioscience industry. Mr. Gaul has a BS, Business Administration from Delaware Valley University and an MBA from Florida Institute of Technology.

What is Michael A. Gaul's net worth?

The estimated net worth of Michael A. Gaul is at least $1.53 thousand as of February 19th, 2025. Gaul owns 235 shares of Beyond Air stock worth more than $1,535 as of August 4th. This net worth evaluation does not reflect any other assets that Gaul may own. Learn More about Michael A. Gaul's net worth.

How do I contact Michael A. Gaul?

The corporate mailing address for Gaul and other Beyond Air executives is 825 EAST GATE BOULEVARD SUITE 320, GARDEN CITY NY, 11530. Beyond Air can also be reached via phone at (516) 665-8200 and via email at [email protected]. Learn More on Michael A. Gaul's contact information.

Has Michael A. Gaul been buying or selling shares of Beyond Air?

Michael A. Gaul has not been actively trading shares of Beyond Air over the course of the past ninety days. Most recently, on Wednesday, February 19th, Michael A. Gaul bought 15 shares of Beyond Air stock. The stock was acquired at an average cost of $152.00 per share, with a total value of $2,280.00. Following the completion of the transaction, the chief operating officer now directly owns 235 shares of the company's stock, valued at $35,720. Learn More on Michael A. Gaul's trading history.

Who are Beyond Air's active insiders?

Beyond Air's insider roster includes Amir Avniel (COO), Douglas Beck (CFO), Ron Bentsur (Director), Robert Carey (Director), Michael Gaul (COO), Steven Lisi (CEO), and Erick Lucera (Director). Learn More on Beyond Air's active insiders.

Are insiders buying or selling shares of Beyond Air?

In the last year, Beyond Air insiders bought shares 2 times. They purchased a total of 39,062 shares worth more than $224,997.12. The most recent insider tranaction occured on July, 29th when CEO Robert Scott Goodman bought 34,722 shares worth more than $199,998.72. Insiders at Beyond Air own 10.0% of the company. Learn More about insider trades at Beyond Air.

Information on this page was last updated on 7/29/2026.

Michael A. Gaul Insider Trading History at Beyond Air

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/19/2025Buy15$152.00$2,280.00235View SEC Filing Icon  
6/30/2023Buy12$1,804.00$21,648.00195View SEC Filing Icon  
3/24/2023Buy2$2,460.00$4,920.00182View SEC Filing Icon  
3/7/2023Buy20$2,344.00$46,880.00180View SEC Filing Icon  
8/22/2022Buy5$3,768.00$18,840.00160View SEC Filing Icon  
See Full Table

Michael A. Gaul Buying and Selling Activity at Beyond Air

This chart shows Michael A Gaul's buying and selling at Beyond Air by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Beyond Air Company Overview

Beyond Air logo
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Read More

Today's Range

Now: $6.53
Low: $6.10
High: $6.95

50 Day Range

MA: $7.66
Low: $5.16
High: $9.90

2 Week Range

Now: $6.53
Low: $5.02
High: $95.60

Volume

40,228 shs

Average Volume

169,691 shs

Market Capitalization

$4.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23